Integrated Filing — IndAS



General information about company

Scrip Code 500288
NSE Symbol MOREPENLAB
MSEI Symbol NOTLISTED
ISIN INE083A01026
Name of company MOREPEN LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 27-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 27-10-2026   11:30:00
End date and time of board meeting 27-10-2026   13:25:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 74,650.19 1,31,663.00
Other income 868.52 1,386.86
Total income 75,518.71 1,33,049.86
2 Expenses
(a) Cost of materials consumed 41,190.55 74,028.60
(b) Purchases of stock-in-trade 695.03 1,659.12
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (3,001.04) (4,932.83)
(d) Employee benefit expense 7,968.94 14,213.29
(e) Finance costs 519.24 1,003.37
(f) Depreciation, depletion and amortisation expense 1,006.99 1,841.87
(f) Other Expenses
1 Power and Fuel 1,319.13 2,599.80
2 Travelling Expenses 784.84 1,349.50
3 Selling and Distribution Expenses 7,830.16 13,161.59
4 Other Expenses 5,550.92 9,018.86
Total other expenses 15,485.05 26,129.75
Total expenses 63,864.76 1,13,943.17
3 Total profit before exceptional items and tax 11,653.95 19,106.69
4 Exceptional items 0.00 0.00
5 Total profit before tax 11,653.95 19,106.69
6 Tax expense
7 Current tax 2,070.35 3,889.20
8 Deferred tax 694.51 693.82
9 Total tax expenses 2,764.86 4,583.02
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 8,889.09 14,523.67
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.38 5.74
16 Total profit (loss) for period 8,889.47 14,529.41
17 Other comprehensive income net of taxes 6.73 25.74
18 Total Comprehensive Income for the period 8,896.20 14,555.15
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0.00 0.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0.00 0.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 10,958.41 10,958.41
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.62 2.65
Diluted earnings (loss) per share from continuing operations 1.62 2.65
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.62 2.65
Diluted earnings (loss) per share from continuing and discontinued operations 1.62 2.65
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on October 27, 2026. A Limited review of the same has been carried out by the Statutory Auditors. 2. The shareholders of the company approved final dividend of Rs. 0.20 per equity share of the face value of Rs. 2.00 each, in their Annual General meeting held on September 26, 2026, and dividend was paid on October 13, 2026. 3. On October 14, 2026 the company received a favourable order from Hon'ble High Court of Himachal Pradesh, Shimla wherein the SCN issued by the Office of the Commissioner, Central GST & Central Excise Commissionerate, Shimla seeking recovery of Rs.117.94 crores was quashed and disposed of the writ petition. Thereby the company has considered the contingent liability of Rs.317.37 crores (inclusive of recovery amount, interest and penality) as disposed off. 4. The above results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (“Ind AS”) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 5. The Company is engaged in the Pharmaceutical Business Segment.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 42,135.47
Capital work-in-progress 2,279.85
Investment property 0.00
Goodwill 0.00
Other intangible assets 16,156.93
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method
Non-current financial assets
Non-current investments 10,178.67
Trade receivables, non-current 0.00
Loans, non-current 8.30
Other non-current financial assets
1 Other non-current financial assets 758.72
Total of other non-current financial assets 758.72
Total non-current financial assets 10,945.69
Deferred tax assets (net)
Other non-current assets
1 Other non-current assets 15,078.68
Total of other non-current assets 15,078.68
Total non-current assets 86,596.62
2 Current assets
Inventories 32,357.63
Current financial asset
Current investments 1,627.61
Trade receivables, current 34,451.61
Cash and cash equivalents 15,495.77
Bank balance other than cash and cash equivalents 9,970.47
Loans, current 45.51
Other current financial assets
Total of other current financial assets 1,342.17
Total current financial assets 62,933.14
Current tax assets (net)
Other current assets
1 Other current assets 48,705.08
Total of other current assets 48,705.08
Total current assets 1,43,995.85
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 2,30,592.47
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 10,958.41
Other equity 1,27,154.84
Total equity attributable to owners of parent 1,38,113.25
Non controlling interest 75.56
Total equity 1,38,188.81
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 12,119.34
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease Liabilities 881.40
2 Other non-current financial liabilities 316.90
Total of other non-current financial liabilities 1,198.30
Total non-current financial liabilities 13,317.64
Provisions, non-current 4,151.61
Deferred tax liabilities (net) 2,342.04
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 19,811.29
Current liabilities
Current financial liabilities
Borrowings, current 18,377.46
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 207.75
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 40,596.25
Total Trade payable 40,804.00
Other current financial liabilities
1 Lease Liabilities 919.01
2 Other current financial liabilities 6,475.62
Total of other current financial liabilities 7,394.63
Total current financial liabilities 66,576.09
Other current liabilities 1,778.99
1 Other current liabilities 1,778.99
Total of other current liabilities 1,778.99
Provisions, current 4,237.29
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 72,592.37
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 92,403.66
Total equity and liabilites 2,30,592.47
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gain on Defined Benefit Plans 12.96 36.19
2 Income tax relating to items that will not be reclassified to profit or loss (4.89) (9.11)
Total Amount of items that will not be reclassified to profit and loss 8.07 27.08
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Exchange Difference on trasnlation of foreign operations (1.34) (1.34)
Total Amount of items that will be reclassified to profit and loss (1.34) (1.34)
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 6.73 25.74



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 19,106.69
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,003.37
Adjustments for decrease (increase) in inventories (5,175.00)
Adjustments for decrease (increase) in trade receivables, current (1,137.86)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (9,604.49)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 0.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 11,265.07
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,841.87
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 36.19
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (1.34)
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 5.74
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,766.45)
Net cash flows from (used in) operations 17,340.24
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 4,592.13
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 12,748.11
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 6.90
Purchase of property, plant and equipment 6,478.18
Proceeds from sales of investment property 609.72
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 2,487.32
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 2,179.29
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (10,528.17)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 11,621.18
Repayments of borrowings 593.43
Payments of lease liabilities (483.94)
Dividends paid 1,085.78
Interest paid 1,003.37
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 734.32
Net cash flows from (used in) financing activities 10,156.86
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 12,376.80
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 12,376.80
Cash and cash equivalents cash flow statement at beginning of period 3,118.97
Cash and cash equivalents cash flow statement at end of period 15,495.77